BR0314089A - Sacarìdeos modificados, conjugados do mesmo e sua fabricação - Google Patents

Sacarìdeos modificados, conjugados do mesmo e sua fabricação

Info

Publication number
BR0314089A
BR0314089A BR0314089-0A BR0314089A BR0314089A BR 0314089 A BR0314089 A BR 0314089A BR 0314089 A BR0314089 A BR 0314089A BR 0314089 A BR0314089 A BR 0314089A
Authority
BR
Brazil
Prior art keywords
conjugates
linker
new
manufacture
modified saccharides
Prior art date
Application number
BR0314089-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Aldo Giannozzi
Francesco Norelli
Paolo Costantino
Giovanni Averani
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Publication of BR0314089A publication Critical patent/BR0314089A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0314089-0A 2002-08-30 2003-09-01 Sacarìdeos modificados, conjugados do mesmo e sua fabricação BR0314089A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture
PCT/IB2003/004194 WO2004019992A1 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture

Publications (1)

Publication Number Publication Date
BR0314089A true BR0314089A (pt) 2005-11-16

Family

ID=9943241

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314089-0A BR0314089A (pt) 2002-08-30 2003-09-01 Sacarìdeos modificados, conjugados do mesmo e sua fabricação

Country Status (16)

Country Link
US (2) US8895516B2 (OSRAM)
EP (1) EP1534342B1 (OSRAM)
JP (2) JP5268222B2 (OSRAM)
CN (2) CN101863998B (OSRAM)
AT (1) ATE319481T1 (OSRAM)
AU (1) AU2003260921B2 (OSRAM)
BR (1) BR0314089A (OSRAM)
CA (1) CA2497167C (OSRAM)
DE (1) DE60303961T2 (OSRAM)
DK (1) DK1534342T3 (OSRAM)
ES (1) ES2260682T3 (OSRAM)
GB (1) GB0220198D0 (OSRAM)
MX (1) MXPA05002315A (OSRAM)
NZ (1) NZ538703A (OSRAM)
RU (2) RU2005108992A (OSRAM)
WO (1) WO2004019992A1 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CN101926988B (zh) * 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
ES2533248T3 (es) * 2005-05-06 2015-04-08 Novartis Ag Inmunógenos para vacunas contra Meningitidis A
PT1973564T (pt) 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vacina compreendendo conjugados polissacarídicos capsulares de streptococcus pneumoniae
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
SG177310A1 (en) 2009-06-22 2012-02-28 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
BR112012010223A2 (pt) * 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
MX350142B (es) 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
SG187912A1 (en) 2010-09-10 2013-04-30 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES2701169T3 (es) * 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
KR102428253B1 (ko) * 2016-03-15 2022-08-02 엠에스디 웰컴 트러스트 힐레맨 랩스 피브이티. 리미티드 신규한 다당류-단백질 접합체 및 이의 제조방법
PL3506935T3 (pl) 2016-09-02 2024-06-10 Sanofi Pasteur, Inc. Szczepionka przeciwko Neisseria meningitidis
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
EP3589314A4 (en) * 2017-02-24 2021-04-21 Merck Sharp & Dohme Corp. INCREASED IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE PROTEIN CONJUGATES
CN117018172A (zh) 2017-09-07 2023-11-10 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
BR112020004471A8 (pt) 2017-09-07 2022-11-01 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
US20220152183A1 (en) * 2019-03-08 2022-05-19 Glaxosmithkline Biologicals Sa Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
EP0447171B1 (en) * 1990-03-15 1994-11-02 Tanabe Seiyaku Co., Ltd. Polysulfate of cyclodextrin derivative and process for preparing the same
AU7948494A (en) * 1993-12-28 1995-07-17 Pfizer Inc. Steroidal glycosides
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
CA2246760C (en) * 1997-01-21 2012-01-10 Pasteur Merieux Serums & Vaccins Polysaccharide-peptide-conjugates
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
CA2266718C (en) * 1997-08-08 2007-05-22 Behringwerke Aktiengesellschaft Polysaccharide conjugates of biomolecules
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
NZ535968A (en) * 2002-03-26 2006-08-31 Chiron S Modified saccharides having improved stability in water
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Also Published As

Publication number Publication date
EP1534342B1 (en) 2006-03-08
US8895516B2 (en) 2014-11-25
RU2005108992A (ru) 2005-11-10
ES2260682T3 (es) 2006-11-01
CA2497167A1 (en) 2004-03-11
RU2008150551A (ru) 2010-06-27
CN1688343B (zh) 2010-09-08
CA2497167C (en) 2011-07-12
EP1534342A1 (en) 2005-06-01
JP5268222B2 (ja) 2013-08-21
US20150166593A1 (en) 2015-06-18
DK1534342T3 (da) 2006-07-10
ATE319481T1 (de) 2006-03-15
CN101863998A (zh) 2010-10-20
AU2003260921A1 (en) 2004-03-19
JP2012017342A (ja) 2012-01-26
WO2004019992A1 (en) 2004-03-11
NZ538703A (en) 2006-09-29
JP5314745B2 (ja) 2013-10-16
RU2531909C2 (ru) 2014-10-27
CN101863998B (zh) 2012-08-29
DE60303961D1 (de) 2006-05-04
MXPA05002315A (es) 2005-06-08
DE60303961T2 (de) 2006-10-26
CN1688343A (zh) 2005-10-26
GB0220198D0 (en) 2002-10-09
JP2006511465A (ja) 2006-04-06
AU2003260921B2 (en) 2008-03-06
US20060263390A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
BR0314089A (pt) Sacarìdeos modificados, conjugados do mesmo e sua fabricação
ATE409048T1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
RU2412944C2 (ru) Иммуногены для вакцин против менингита а
WO2005030258A3 (en) Small molecule compositions and methods for increasing drug efficiency using compositions thereof
UY26815A1 (es) Métodos para tratar enfermedades reumáticas al usar una molécula ctla4 soluble
WO2005007197A3 (en) Conjugated biological molecules and their preparation
PL410219A1 (pl) Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
UA95237C2 (uk) Імуногенна композиція
MXPA03011681A (es) Uso de inhibidores de epoxido hidrolasa soluble, para tratar enfermedades relacionadas con la enfermedad cardiovascular.
PT751144E (pt) Novos pro-farmacos antraciclinicos, metodo para preparacao e tambem a sua utilizacao em quimioterapia selectiva
MA30609B1 (fr) Imidazolidine-2,4-diones arylaminoaryl-alkyl-substituees, leur procede de synthese, les medicaments comprenant ces composes, et leurs applications.
BR0207640A (pt) Composição farmacêutica oral de cefpodoxima proxetil
ATE464066T1 (de) Neisseria meningitidis igtb los als adjuvans
ATE225771T1 (de) Prostaglandin-pharmazeutische-zusammensetzungen
AU2002215904A1 (en) Compounds with a branched linker
EP1775289A4 (en) NEW IMIDAZOLIDINE DERIVATIVES
CA2423007A1 (en) Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients
GB0501964D0 (en) Chemical compounds
TR200402546T4 (tr) Taksan türevleri hazırlamak için işlem.
EP1996217A4 (en) NOVEL ANTIBIOTIC COMPOSITIONS
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
DK1250335T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner
FR2874924A1 (fr) Hexadecasaccharides biotinyles, leur preparation et leur utilisation therapeutique
WO2007050789A3 (en) Glycosyl-oligonucleotide conjugates and methods

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, S.R.L. (IT)

Free format text: ALTERADO DE: CHIRON SRL.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07H 13/12 (2006.01), A61K 47/64 (2017.01)

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/715 (2006.01), A61K 47/64 (2017.01), C07H

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements